Literature DB >> 9072586

Surgery for a post-chemotherapy residual mass in seminoma.

H W Herr1, J Sheinfeld, H S Puc, R Heelan, D F Bajorin, P Mencel, G J Bosl, R J Motzer.   

Abstract

PURPOSE: We attempted to select patients for surgery of post-chemotherapy residual mass in advanced seminoma.
MATERIALS AND METHODS: A total of 55 patients with advanced seminoma underwent surgical exploration of a mass seen on computerized tomography (CT) after chemotherapy. Residual masses were defined radiographically as smaller or larger than 3 cm. and as well defined or poorly defined. Surgery consisted of complete resection of the mass and surrounding lymph nodes or multiple biopsies at sites of disease.
RESULTS: Of the 55 patients 32 (58%) had masses resected and 23 (42%) underwent multiple biopsies. Of 27 patients with a post-chemotherapy 3 cm. or larger mass on CT 8 (30%) had residual tumor (seminoma in 6 and teratoma in 2), whereas necrotic tissue was found in the other 28 patients having a mass smaller than 3 cm. Well defined masses on CT were resected in 78% of patients and poorly defined masses could be resected in only 44%. Of the 8 patients with positive histology 6 remain alive and disease-free after complete resection of a well defined, larger than 3 cm. mass containing viable tumor, and 2 with a poorly defined mass died after biopsy only of residual seminoma despite salvage therapy. Three other patients who underwent complete resection of necrotic masses subsequently had relapse at distant sites and died. Median followup was 47 months (range 5 +/- 153+ months).
CONCLUSIONS: Patients with advanced seminoma who have a residual mass smaller than 3 cm. after chemotherapy do not benefit from surgery. For patients with a residual mass 3 cm. or larger we prefer surgery to define response, resect viable tumor when possible and direct further treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9072586

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  Primary malignant bone tumors and solitary metastases of the thoracolumbar spine: results by management with total en bloc spondylectomy.

Authors:  Ingo Melcher; Alexander C Disch; Cyrus Khodadadyan-Klostermann; Stefan Tohtz; Mirko Smolny; Ulrich Stöckle; Norbert P Haas; Klaus-Dieter Schaser
Journal:  Eur Spine J       Date:  2007-01-25       Impact factor: 3.134

Review 4.  Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.

Authors:  Mehmet Asim Bilen; Houssam Hariri; Chady Leon; Charles C Guo; Deborah A Kuban; Louis L Pisters; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2014-02-28       Impact factor: 2.872

Review 5.  Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?

Authors:  Stephen B Riggs; Earl F Burgess; Kris E Gaston; Caroline A Merwarth; Derek Raghavan
Journal:  Oncologist       Date:  2014-04-09

Review 6.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

7.  Regression of metastatic seminoma in a patient referred for carcinoma of unknown primary origin.

Authors:  John E Musser; Christopher G Przybycin; Paul Russo
Journal:  Nat Rev Urol       Date:  2010-07-06       Impact factor: 14.432

8.  Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors.

Authors:  Hugh J Lavery; Robert R Bahnson; David S Sharp; Kamal S Pohar
Journal:  Ther Adv Urol       Date:  2009-10

Review 9.  Late relapse of germ cell tumors.

Authors:  Jan Oldenburg; Rolf Wahlqvist; Sophie D Fosså
Journal:  World J Urol       Date:  2009-04-17       Impact factor: 4.226

Review 10.  Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Authors:  Hester Lieng; Padraig Warde; Philippe Bedard; Robert J Hamilton; Aaron R Hansen; Michael A S Jewett; Martin O'malley; Joan Sweet; Peter Chung
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.